An Intervention Study of Intermittent Fasting and Low Carbon Diet in Patients With Metabolic Syndrome

Study start date: July 12, 2020

Inclusion criteria 1. Diagnosed with metabolic syndrome (i.e., more than 3 abnormal findings out of 5): 1. Waist circumference ≥ 90 cm (men) or ≥ 80 cm (women). 2. Elevated TG (use of medications for elevated TG is an alternate indicator) ≥ 150 mg/dL (1.7 mmol/L). 3. Reduced HDL-c (use of medications for reduced HDL-c is an alternate indicator) \< 40 mg/dL (1.0 mmol/L) in males \< 50 mg/dL (1.3 mmol/L) in females. 4. Elevated blood pressure (use of hypoglycemic medications is an alternate indicator). SBP ≥ 130 and/or DBP ≥ 85 mmHg. 5. Elevated FBG (used of hypoglycemic medications is an alternate indicator) ≥ 100 mg/dL (5.6 mmol/L). 2. Age from 18 to 65 years. 3. Stable weight (change ≤ 10% current body weight) for 3 months prior to the study. 4. If participates were on hypoglycemic medications, hypotensive medications, lipid-lowering medications and cardiovascular medications, dose adjustment was not permitted during the 3-month intervention. Exclusion criteria 1. Pregnant or breast-feeding. 2. Night shift workers. 3. History of major diseases or related diseases, such as inflammatory disease, rheumatologic disease, adrenal disease, malignancy, type 1 diabetes, cirrhosis, chronic kidney disease, acquired immunodeficiency syndrome, eating disorder, uncontrolled psychiatric disorder and major adverse cardiovascular event. 4. Current participate in other weight-management program, current on a prescribed diet for special disease or current on any drugs that effect appetite. 5. History of weight-loss surgery.